Health ❯ Healthcare ❯ Chronic Diseases

Type 2 Diabetes

Management Strategies Treatment Options Management and Treatment Cardiovascular Risk Obesity Weight Management Medication Effects Blood Sugar Regulation Management Dementia Risk Medication Comparison Cardiovascular Health Prevention and Management Impact on Youth Cardiometabolic Health Insulin Response Metabolic Syndrome Statin Therapy Effects Diabesity Epidemic Metabolic Care Tobacco Use Disorder GLP-1 Receptor Agonists Obesity Management Insulin Sensitivity SGLT-2 Inhibitors Insulin Regulation Associated Conditions Obesity and Diabetes Connection

Lilly’s Oral GLP-1 Orforglipron Tops Oral Semaglutide in Lancet Phase 3 Diabetes Trial

The once-daily small-molecule pill can be taken without empty-stomach restrictions.

Pfizer to Commercialize Sciwind’s GLP-1 Ecnoglutide in China Under Exclusive License

Major Lancet Analysis Finds Most Statin Label Side Effects Not Caused by the Drugs

Oral Semaglutide Cuts Serious Heart-Failure Events 22% in Type 2 Diabetes With Heart Failure

Meta-Analysis Finds GLP-1 Drugs Show Little Short-Term Impact on Obesity-Linked Cancer Risk

Real-World Study Finds Semaglutide and Tirzepatide Cut Cardiovascular Risk in Type 2 Diabetes

EMA Approves Cardiovascular Indication for Novo Nordisk’s Rybelsus

17 Million U.S. Youth Eligible for GLP-1 Therapies Face Coverage and Care Barriers

Glipizide Linked to 13% Higher Cardiovascular Risk Than DPP-4 Inhibitors

GLP-1 Agonists Cut Dementia and Mortality Risk Versus Metformin in Type 2 Diabetes